1	Comparison of SARS-CoV-2 detection in Saliva by real-time RT-PCR and RT-PCR/MALDI-TOF
2	Methods
3	Matthew M. Hernandez <sup>1,2,#</sup> , Radhika Banu <sup>3</sup> , Paras Shrestha <sup>3</sup> , Armi Patel <sup>3</sup> , Feng Chen <sup>3</sup> , Liyong Cao <sup>3</sup> ,
4	Shelcie Fabre <sup>3</sup> , Jessica Tan <sup>1,4</sup> , Heidi Lopez <sup>3</sup> , Numthip Chiu <sup>3</sup> , Biana Shifrin <sup>3</sup> , Inessa Zapolskaya <sup>3</sup> , Vanessa
5	Flores <sup>3</sup> , Pui Yiu Lee <sup>3</sup> , Sergio Castañeda <sup>5</sup> , Juan David Ramírez <sup>5</sup> , Jeffrey Jhang <sup>2</sup> , Giuliana Osorio <sup>3</sup> , Melissa
6	R. Gitman <sup>2,3</sup> , Michael D. Nowak <sup>2,3</sup> , David L. Reich <sup>6</sup> , Carlos Cordon-Cardo <sup>2</sup> , Emilia Mia Sordillo <sup>2,3</sup> ,
7	Alberto E. Paniz-Mondolfi <sup>2,3,#</sup>
8	
9	# Corresponding authors: alberto.paniz-mondolfi@mountsinai.org; matthew.hernandez@mssm.edu
10	
11	Affiliations:
12	<sup>1</sup> Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
13	<sup>2</sup> Department of Pathology, Molecular, and Cell-Based Medicine, Icahn School of Medicine at Mount
14	Sinai, New York, NY 10029, USA
15	<sup>3</sup> Clinical Microbiology Laboratory, Department of Pathology, Molecular, and Cell-Based Medicine,
16	Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
17	<sup>4</sup> The Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY
18	10029, USA
19	<sup>5</sup> Grupo de Investigaciones Microbiológicas-UR (GIMUR), Departamento de Biología, Facultad de
20	Ciencias Naturales, Universidad del Rosario, Bogotá, Colombia.
21	<sup>6</sup> Icahn School of Medicine at Mount Sinai Department of Anesthesiology Perioperative and Pain
22	Medicine, New York, NY, 10029, USA

1

## 23 ABSTRACT

24 The coronavirus disease 2019 (COVID-19) pandemic has accelerated the need for rapid implementation 25 of diagnostic assays for detection of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in 26 respiratory specimens. While multiple molecular methods utilize nasopharyngeal specimens, supply 27 chain constraints and need for easier and safer specimen collection warrant alternative specimen types, 28 particularly saliva. Although saliva has been found to be a comparable clinical matrix for detection of 29 SARS-CoV-2, evaluations of diagnostic and analytic performance across platforms for this specimen 30 type are limited. Here, we compared two methods for SARS-CoV-2 detection in saliva: the Roche 31 cobas® 6800/8800 SARS-CoV-2 real-time RT-PCR Test and the Agena Biosciences MassARRAY® 32 SARS-CoV-2 Panel/MassARRAY<sup>®</sup> System. Overall, both systems had high agreement with one 33 another, and both demonstrated high diagnostic sensitivity and specificity when compared to matched 34 patient upper respiratory specimens. We also evaluated the analytical sensitivity of each platform and 35 determined the limit of detection of the Roche assay was four times lower than that of Agena for saliva 36 specimens (390.6 v. 1,562.5 copies/mL). Furthermore, across individual target components of each 37 assay, T2 and N2 targets had the lowest limits of detection for each platform, respectively. Together, we 38 demonstrate that saliva represents an appropriate specimen for SARS-CoV-2 detection in two 39 technologies that have high agreement and differ in analytical sensitivities overall and across individual 40 component targets. The addition of saliva as an acceptable specimen and understanding the sensitivity 41 for testing on these platforms can further inform public health measures for screening and detection to 42 combat the COVID-19 pandemic.

#### 43 INTRODUCTION

Accurate and rapid testing is vital to informing the response to the coronavirus disease 2019 (COVID-19) pandemic. Since its inception, nucleic acid amplification testing (NAAT) for SARS-CoV-2 RNA in nasopharyngeal (NP) specimens has been the mainstay in diagnosing COVID-19. Collection of such specimens requires sampling by trained healthcare professionals who need materials such as swabs and viral transport medium (VTM) that may not be available in all settings (1–3). Currently, alternative specimen types including anterior nares (AN) and oropharyngeal (OP) specimens have been evaluated and approved for testing.

51 Saliva has recently garnered attention as a potential specimen given its lower discomfort, minimal 52 invasiveness, and ability to be self-collected. As of February 21, 2021, nineteen in vitro SARS-CoV-2 53 diagnostic tests utilizing saliva as a clinical matrix have been approved for Emergency Use Authorization 54 (EUA) by the U.S. Food and Drug Administration (4). Indeed, recent systematic reviews of reported 55 studies demonstrated that saliva NAAT diagnostic performance is comparable to that of NP specimens, 56 particularly in the ambulatory setting (5, 6). While studies have compared detection of SARS-CoV-2 57 across matched NP and saliva specimens, there is large variability in specimen collection, processing 58 methods, and testing platforms utilized (5-14). Moreover, studies that assess analytical performance of 59 detection in saliva across platforms are lacking.

60 Since the identification of SARS-CoV-2, high-throughput sample processing has been logistically 61 difficult to achieve given a number of hurdles including instrument availability and supply chain 62 limitations (15–18). Recently, a novel multiplex reverse transcription (RT-PCR)/MALDI-TOF assay from 63 Agena Bioscience has received EUA (19). The MassARRAY<sup>®</sup> SARS-CoV-2 Panel and MassARRAY<sup>®</sup> 64 System has the potential to increase diagnostic capacity and complement current standard NAAT 65 technologies. This is particularly promising for use of saliva for large community-based testing efforts.

- 66 We therefore evaluated this platform ("Agena") and the more ubiquitous cobas<sup>®</sup> 6800/8800 SARS-CoV-
- 67 2 real-time RT-PCR Test ("Roche") to detect SARS-CoV-2 in saliva specimens. Furthermore, we also
- 68 compared the analytic performance of each platform and each of its component targets.

### 69 MATERIALS AND METHODS

We undertook a direct comparison of saliva as a clinical specimen for detection of SARS-CoV-2
viral nucleic acids across two platforms in the Clinical Microbiology Laboratory (CML) for the Mount
Sinai Health System (MSHS) which is certified under Clinical Laboratory Improvement Amendments of
1988 (CLIA), 42 U.S.C. §263a and meets requirements to perform high-complexity tests.

## 74 Saliva specimen collection and processing

Saliva specimens were collected from sixty patients who underwent molecular testing for SARS-CoV-2 in NP or AN specimens collected within the previous 48 hours. Saliva specimens were collected in sterile containers (Corning, 352070) and volumes ranged from 0.5 to 1.5 mL. Upon receipt in MSHS CML, 1 mL of viral transport media (VTM) (Hardy Diagnostics, R99) was added to each saliva specimen. These saliva-VTM specimens were vortexed for 30 seconds and 1 mL of each was incubated at 55°C for 15 minutes. Processed specimens subsequently underwent side-by-side SARS-CoV-2 nucleic acid detection across two different platforms.

## 82 SARS-CoV-2 testing

For testing with the cobas<sup>®</sup> 6800/8800 SARS-CoV-2 real-time RT-PCR Test (Roche, 09175431190), aliquots of processed saliva specimens were run as previously described for NP specimens (20). Briefly, the assay utilizes two targets to detect SARS-CoV-2 RNA: the SARS-CoV-2-specific Orf1ab gene (T1) and the pan-Sarbecovirus envelope E gene (T2). A result was deemed positive for SARS-CoV-2 if both T1 and T2 were detected, or if T1 was detected alone. A result was deemed presumptive positive if T2 was detected alone. A result was deemed negative if neither T1 nor T2 was detected. Target results were valid across all specimens run.

90 For testing with the MassARRAY<sup>®</sup> SARS-CoV-2 Panel and MassARRAY<sup>®</sup> System (Agena,
 91 CPM384), RNA was extracted from 300 μL of processed specimens using the chemagic<sup>TM</sup> Viral

92 DNA/RNA 300 Kit H96 (PerkinElmer, CMG-1033-S) on the automated chemagic<sup>TM</sup> 360 instrument 93 (PerkinElmer, 2024-0020), as per the manufacturer's protocol. To serve as an internal control (IC), MS2 94 phage RNA was included in all extraction steps. Extracted RNA underwent reverse transcription PCR 95 (RT-PCR) with iPLEX® Pro chemistry to amplify the different Agena target regions per the 96 manufacturer's protocol. After the inactivation of unincorporated dNTPs by treatment with shrimp 97 alkaline phosphatase (SAP), a sequence-specific primer extension step was performed, in which a mass-98 modified terminator nucleotide was added to the probe, using the supplied extension primers and iPLEX® 99 Pro reagents.

100 The extension products (analyte) were desalted, transferred to a SpectroCHIP® Array (a silicon 101 chip with pre-spotted matrix crystal) and then loaded into the MassARRAY® Analyzer (a MALDI-TOF 102 mass spectrometer). For the sample analysis, the analyte/matrix co-crystals were irradiated by a laser, 103 inducing desorption and ionization. The positively charged molecules accelerated into a flight tube 104 towards a detector. Separation occurred by time-of-flight, which is proportional to the mass of the 105 individual molecules. After data processing, a spectral fingerprint was generated for each analyte that 106 characterizes the mass/charge ratio of the molecules (x-axis) as well as their relative intensity (y-axis). Data acquired by the MassARRAY<sup>®</sup> Analyzer was processed with the MassARRAY<sup>®</sup> Typer software and 107 108 then the SARS-CoV-2 Report software. The assay was designed to detect five viral targets: three in the 109 nucleocapsid (N) gene (N1, N2, N3) and two in the Orf1ab gene (ORF1, Orf1ab). If the MS2 IC was 110 detected, results were interpreted as positive if at least two targets were detected or negative if less than 111 two targets were detected. If MS2 IC was not detected and no targets were detected, the result was 112 interpreted as invalid and required rerunning of the specimen.

## 113 Limit of detection of SARS-CoV-2 nucleic acid in saliva

The limit of detection (LoD) was determined across both platforms using known concentrations
of a SARS-CoV-2 standard spiked into saliva clinical matrix.

116 Briefly, an in-house SARS-CoV-2 standard was generated by pooling 59 NP specimens that 117 previously tested positive at MSHS CML (average T1 cycle threshold (Ct) = 17.53, average T2 Ct = 118 17.59). To quantitate the standard, three dilutions of the pooled sample were made (e.g., 1:50,000 (D1), 119 1:100,000 (D2), 1:200,000 (D3)) and run alongside serial dilutions of a commercially available standard 120 (ZeptoMetrix, NATSARS(COV2)-ERC) on the Roche platform which has EUA from the FDA for SARS-121 CoV-2 detection in NP specimens. All reactions were run in triplicate and SARS-CoV-2-negative NP 122 matrix served as the diluent. Concentrations of each standard dilution was determined by extrapolation 123 from standard curves generated across T1 and T2 targets (Fig. S1) for each dilution. The stock 124 concentration was, in turn, calculated as the average of the extrapolated stock concentrations determined 125 at each dilution. Aliquots (50 µL) of this stock measurand were stored at -80°C to prevent multiple freeze-126 thaw cycles.

127 To simulate collection of saliva for testing, saliva from healthy donors was combined in equal 128 parts with VTM and spiked with the SARS-CoV-2 measurand. Serial dilutions of the spiked saliva-VTM 129 specimens were generated in 50-mL conical vials (Corning 352070) over a range of 3,125.0 - 97.7 130 copies/mL (cp/mL) and 12,500 – 195.3 cp/mL for testing on the Roche and Agena platforms, respectively. 131 For each platform, ten replicates of each dilution were generated as well as ten replicates of saliva-VTM 132 spiked with the SARS-CoV-2-negative NP diluent to serve as negative controls. Spiked saliva-VTM 133 specimens were processed and run as described above. SARS-CoV-2 was not detected in any of the 134 negative controls and all results were valid across both platforms.

For each platform, the LoD of each overall assay and each target were determined. The experimental LoD represents the lowest concentration with 95% detection. The probit LoD (and 95% fiduciary confidence intervals) was determined by 95% detection based on a probit regression model.

#### 138 Statistical analyses

139 For comparison of outcomes across both platforms, percent agreement and Cohen's kappa ( $\kappa$ ) 140 statistic were calculated using the attribute agreement analysis on Minitab Statistical Software 141 (19.2020.2.0). Normality was assessed by D'Agostino and Pearson test for continuous variables (e.g., Ct 142 values) (GraphPad Prism 9.0.2). Student's t-test (two-tailed) was performed if data was normally 143 distributed; otherwise, the Mann-Whitney test (two-tailed) was utilized (GraphPad Prism 9.0.2). Simple 144 linear regression analyses were performed across Roche Ct values and serial dilutions. Probit regression 145 modeling assuming Weibull distribution was performed if at least two probit points were available (e.g., 146 not 100% or 0% detection) (Minitab Statistical Software, 19.2020.2.0). Where depicted, confidence 147 intervals (CI) reflect the 95% level.

#### 148 **RESULTS**

Sixty patients who underwent testing for SARS-CoV-2 by NAAT (NP or AN) at MSHS CML
were provided with sterile containers for submission of saliva specimens within 48 hours of diagnosis.
Saliva specimens were immediately processed and run side-by-side on the Roche and Agena platforms.
When compared to paired NP or AN specimens, both platforms had equivalent sensitivities (97.14%, CI:
85.08-99.93%) and specificities (100%, CI: 86.28-100%) for saliva specimens.

The Roche platform detected SARS-CoV-2 RNA in 34/60 saliva specimens (Table 1). Of the remaining 26, two specimens resulted as presumptive positive and were considered not detected for this study. The Agena platform detected SARS-CoV-2 RNA in 34/60 specimens. Of note, one of the two presumptive positive specimens by Roche was detected by Agena. In addition, the one specimen detected by Roche but not by Agena had the highest T1 Ct (31.62) and second highest T2 Ct (33.68) of all specimens tested. Overall, there was an almost perfect level of agreement across the two platforms (96.67% agreement, CI: 88.47-99.59; Cohen's  $\kappa = 0.9321$ , p = 2.6x10<sup>-13</sup>).

To preliminarily assess the sensitivity of each platform, we evaluated the performance of component targets across the saliva clinical specimens (Fig. 1). Roche Ct values for each target ranged from 18.80-31.62 for target T1 (Orf1ab gene) and 19.06-37.46 for target T2 (E gene). When compared to the number of targets detected on the Agena platform, all five Agena targets were detected in specimens that had the lowest mean ( $\pm$ SD) Ct values on Roche T1 (24.64 $\pm$ 3.019) and T2 (25.26 $\pm$ 3.189) targets. The number of Agena targets detected in clinical saliva specimens progressively decreased with increasing Ct values across both Roche targets.

We next systematically measured the limit of detection (LoD) of each platform and the component targets. We generated a SARS-CoV-2 standard from high-titer positive NP specimens collected from MSHS patients diagnosed at CML. The titer of the in-house standard was determined by extrapolating

171 concentrations of three dilutions run alongside serial dilutions of a commercial SARS-CoV-2 standard on 172 the Roche platform (Fig. S1). This had the benefit of accounting for any variation in extraction efficiency. 173 The in-house standard was spiked into saliva matrix collected from healthy donors and ten 174 replicates of serial dilutions were run side-by-side on each platform. On the Agena platform, the 175 experimental LoD was determined to be 1,562.5 cp/mL (Table 2) which is slightly lower than the LoD 176 reported by manufacturers for NP clinical matrix (2,500 cp/mL) (19). Across the five different Agena 177 targets, the most sensitive target was the N2 target (1,562.5 cp/mL) followed by the N1 target (3,125 178 cp/mL) (Table 2, Fig. 2A). The least sensitive was the Orflab target whose LoD could not be determined 179 from the range of concentrations tested. This reflected a gradient in performance across the individual 180 components on the Agena platform.

181 On the Roche platform, the experimental LoD was lower than that of Agena at 390.6 cp/mL. The 182 Ct values for these saliva specimens demonstrated a linear correlation with the corresponding concentrations across both T1 (R<sup>2</sup>=0.9760, p=0.0016) and T2 (R<sup>2</sup>=0.9534, p=0.008) (Fig. 2B). Overall, 183 184 T2 Ct values were higher than T1 Ct values for specimens at the same concentration (p < 0.01) which is 185 consistent with previous reports for NP specimens (21, 22). While the experimental LoD for T1 and T2 186 targets were determined equivalent, probit analyses suggest the LoD of T2 is, in fact, lower (228.6 cp/mL). 187 However, the fiduciary confidence interval for this value is broad  $(151.4-3.7 \times 10^{10})$  given that the concentration at which no specimens were detected was not determined in our study. 188

#### 189 **DISCUSSION**

190 Saliva represents an attractive alternative specimen type for SARS-CoV-2 testing given its limited 191 invasiveness, ability to be self-collected, and reduced need for limited supplies A number of groups have 192 demonstrated that saliva is an acceptable and sensitive specimen type when compared to other upper 193 respiratory (e.g., NP, AN, OP) specimens (5, 8, 9, 12–14). However, analytical performance of this 194 specimen type has yet to be evaluated across the multitude of platforms utilized. In this study, we 195 demonstrate the utility of saliva as a diagnostic specimen across the Roche and Agena platforms. Saliva 196 specimens collected within two days are equivocally sensitive and specific across both methods when 197 compared to matched NP or AN specimens.

198 It is important to note that these two platforms tested are distinguished from each other by their 199 technologic basis and their molecular targets. The Roche platform is like most of the current SARS-CoV-200 2 molecular diagnostic assays in that it utilizes real-time RT-PCR for detection. However, the Agena 201 platform utilizes mass spectrometry to detect targeted amplicons produced by RT-PCR. While distinct in 202 platform technology, our findings demonstrate comparable diagnostic capabilities of both platforms for 203 detection of SARS-CoV-2 nucleic acids in clinical saliva specimens (Table 1).

The platforms we evaluated also differed by SARS-CoV-2 viral targets probed. In contrast to the Roche platform, which is based on two target amplicons (SARS-CoV-2 Orf1ab (T1) and pan-Sarbecovirus E genes (T2)), the Agena platform probes for five targets across two viral genes (3 targets in the nucleocapsid gene (N1, N2, N3), 2 targets in the Orf1ab gene (ORF1, Orf1ab)). This redundancy in viral targets is required to ensure robust sensitivity. When we assessed analytic performance of each target across the clinical saliva specimens, we observed variation in target performance with decreasing viral titers (e.g., Ct values), particularly within the Agena platform (Fig. 1). Specifically, the number of Agena

211 targets detected progressively dropped with decreasing concentration. This suggested inherent analytic
212 differences in the component targets that warrant further investigating.

213 In order to effectively utilize saliva as a clinical specimen for SARS-CoV-2 testing, it is essential 214 to characterize the analytical sensitivity for each diagnostic platform. Most studies have yet to evaluate 215 the LoD across platforms in a standardized method for saliva specimens (reviewed in (6)). Moreover, 216 analytic sensitivity of component targets are often reported as those described by manufacturers or are not 217 systematically evaluated, reported, nor compared across platforms (6, 7, 23–25). Our study demonstrates 218 a greater sensitivity in the Roche platform for saliva specimens overall (Fig. 2). We also demonstrate that 219 across both platforms, there are some targets which are more sensitive than others such as N2 in Agena 220 and T2 in Roche (Fig. 2, Table 2). These metrics are vital as they can inform how diagnostic labs address 221 new circulating viral variants that have mutations that may interfere with multiple detection methods.

Our study does have limitations in that our saliva collection methods did not occur at one time point but rather at any point in the day within two days of initial NP/AN collection. While the utility of standardized collection methods (e.g., early morning collection) remain to be further clarified, this is not a variable we controlled in this study. In addition, we utilized a pooled positive NP specimen to serve as our analyte to assess sensitivity. As a result, the sensitivities measured are based on a potentially heterogenous mixture of viral variants. We addressed this by pooling specimens isolated from two consecutive days to ensure a sampling of the predominant circulating clade virus at the given time period.

Overall, we demonstrate comparable analytical performance across two unique diagnostic platforms for detection of SARS-CoV-2 nucleic acids in saliva specimens. Given the continued spread and rise of new SARS-CoV-2 variants, there is a critical need to understand the analytic capabilities of these technologies. This is especially relevant in large-scale screening efforts where saliva has the potential to be further exploited for its utility as a clinical specimen. This greater understanding of assay

- and target sensitivity is essential to informing both effective detection efforts and broader public health
- 235 measures to ultimately quell the COVID-19 pandemic.

# 236 ACKNOWLEDGMENTS

- We thank the members of the MSHS CML for providing any assistance when needed throughout this study. We also would like to thank the patients and healthy donors for providing specimens to complete this study.
- 240

#### 241 AUTHOR CONTRIBUTIONS

- 242 M.M.H., R.B., P.S., S.F., J.T., A.E.PM., H.L., M.R.G., M.D.N., and E.M.S. provided clinical samples for
- 243 the study. M.M.H., R.B., P.S., A.P., F.C., L.C., H.L., N.C., G.O., B.S., I.Z., V.F., P.Y., and, A.E.PM.
- 244 accessioned clinical samples. M.M.H., R.B., P.S., A.P., F.C., L.C., and A.E.PM. performed limit of
- 245 detection studies. M.M.H., L.S.G., J.D.R., J.J., D.L.R., C.C.C., E.M.S., and A.E.PM. analyzed,
- interpreted, or discussed data. M.M.H. and A.E.PM. wrote the manuscript. M.M.H., R.B., and A.E.PM.
- 247 conceived the study. M.M.H., R.B., and A.E.PM. supervised the study. DLR raised financial support.
- 248

## 249 COMPETING INTERESTS

250 The authors have no conflicts or competing interests to disclose.

# 251 **REFERENCES**

- 1. Lieberman JA, Pepper G, Naccache SN, Huang M-L, Jerome KR, Greninger AL. 2020.
- 253 Comparison of Commercially Available and Laboratory-Developed Assays for In Vitro Detection
- of SARS-CoV-2 in Clinical Laboratories. J Clin Microbiol 58.
- 255 2. Kaul KL. 2020. Laboratories and Pandemic Preparedness: A Framework for Collaboration and
- 256 Oversight. J Mol Diagn 22:841–843.
- 257 3. Zehnbauer B. 2021. Diagnostics in the Time of Coronavirus Disease 2019 (COVID-19):
- 258 Challenges and Opportunities. J Mol Diagn 23:1–2.
- 4. Febraury 17, 2021. In Vitro Diagnostics EUAs. US Food and Drug Administration.
- 260 5. Butler-Laporte G, Lawandi A, Schiller I, Yao MC, Dendukuri N, McDonald EG, Lee TC. 2021.
- 261 Comparison of Saliva and Nasopharyngeal Swab Nucleic Acid Amplification Testing for Detection
- 262 of SARS-CoV-2: A Systematic Review and Meta-analysis. JAMA Intern Med
- 263 https://doi.org/10.1001/jamainternmed.2020.8876.
- 264 6. Lee RA, Herigon JC, Benedetti A, Pollock NR, Denkinger CM. 2021. Performance of Saliva,
- 265 Oropharyngeal Swabs, and Nasal Swabs for SARS-CoV-2 Molecular Detection: A Systematic
- 266 Review and Meta-analysis. J Clin Microbiol https://doi.org/10.1128/JCM.02881-20.
- 267 7. Yee R, Truong TT, Pannaraj PS, Eubanks N, Gai E, Jumarang J, Turner L, Peralta A, Lee Y, Dien
- Bard J. 2021. Saliva Is a Promising Alternative Specimen for the Detection of SARS-CoV-2 in
- 269 Children and Adults. J Clin Microbiol 59.
- 270 8. Procop GW, Shrestha NK, Vogel S, Van Sickle K, Harrington S, Rhoads DD, Rubin BP, Terpeluk
- 271 P. 2020. A Direct Comparison of Enhanced Saliva to Nasopharyngeal Swab for the Detection of
- 272 SARS-CoV-2 in Symptomatic Patients. J Clin Microbiol 58.

273	9.	Wvllie AL	. Fournier J.	Casanovas-	Massana A.	Campbell M.	Tokuvama	M. Viia	vakumar P.	Warren
415	<i>.</i>				TITADDAILA I LA	Cumpoon ma	I OILG J GIIIG	1714 7 1 <b>1</b> M	y with with a r	, ,, all ol

- JL, Geng B, Muenker MC, Moore AJ, Vogels CBF, Petrone ME, Ott IM, Lu P, Venkataraman A,
- 275 Lu-Culligan A, Klein J, Earnest R, Simonov M, Datta R, Handoko R, Naushad N, Sewanan LR,
- 276 Valdez J, White EB, Lapidus S, Kalinich CC, Jiang X, Kim DJ, Kudo E, Linehan M, Mao T,
- 277 Moriyama M, Oh JE, Park A, Silva J, Song E, Takahashi T, Taura M, Weizman O-E, Wong P,
- 278 Yang Y, Bermejo S, Odio CD, Omer SB, Dela Cruz CS, Farhadian S, Martinello RA, Iwasaki A,
- 279 Grubaugh ND, Ko AI. 2020. Saliva or Nasopharyngeal Swab Specimens for Detection of SARS-
- 280 CoV-2. N Engl J Med 383:1283–1286.
- 281 10. Ceron JJ, Lamy E, Martinez-Subiela S, Lopez-Jornet P, Capela E Silva F, Eckersall PD,
- 282 Tvarijonaviciute A. 2020. Use of Saliva for Diagnosis and Monitoring the SARS-CoV-2: A
- 283 General Perspective. J Clin Med Res 9.
- 11. Goldfarb DM, Tilley P, Al-Rawahi GN, Srigley JA, Ford G, Pedersen H, Pabbi A, Hannam-Clark
- 285 S, Charles M, Dittrick M, Gadkar VJ, Pernica JM, Hoang LMN. 2021. Self-collected Saline Gargle
- 286 Samples as an Alternative to Healthcare Worker Collected Nasopharyngeal Swabs for COVID-19
- 287 Diagnosis in Outpatients. J Clin Microbiol https://doi.org/10.1128/JCM.02427-20.
- 288 12. Zhu J, Guo J, Xu Y, Chen X. 2020. Viral dynamics of SARS-CoV-2 in saliva from infected
  289 patients. J Infect.
- 290 13. To KK-W, Tsang OT-Y, Leung W-S, Tam AR, Wu T-C, Lung DC, Yip CC-Y, Cai J-P, Chan JM-
- 291 C, Chik TS-H, Lau DP-L, Choi CY-C, Chen L-L, Chan W-M, Chan K-H, Ip JD, Ng AC-K, Poon
- 292 RW-S, Luo C-T, Cheng VC-C, Chan JF-W, Hung IF-N, Chen Z, Chen H, Yuen K-Y. 2020.
- 293 Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody
- 294 responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect Dis
- 295 20:565–574.

- 14. Teo AKJ, Choudhury Y, Tan IB, Cher CY, Chew SH, Wan ZY, Cheng LTE, Oon LLE, Tan MH,
- 297 Chan KS, Hsu LY. 2021. Saliva is more sensitive than nasopharyngeal or nasal swabs for diagnosis

of asymptomatic and mild COVID-19 infection. Sci Rep 11:3134.

- 299 15. Vandenberg O, Martiny D, Rochas O, van Belkum A, Kozlakidis Z. 2021. Considerations for
- 300 diagnostic COVID-19 tests. Nat Rev Microbiol 19:171–183.
- 16. Lamprou DA. 2020. Emerging technologies for diagnostics and drug delivery in the fight against
   COVID-19 and other pandemics. Expert Rev Med Devices 17:1007–1012.
- 303 17. Younes N, Al-Sadeq DW, Al-Jighefee H, Younes S, Al-Jamal O, Daas HI, Yassine HM, Nasrallah
- 304 GK. 2020. Challenges in Laboratory Diagnosis of the Novel Coronavirus SARS-CoV-2. Viruses
- 305 12.
- 306 18. Sheridan C. 2020. Coronavirus and the race to distribute reliable diagnostics. Nat Biotechnol
  307 38:382–384.
- 308 19. Agena Bioscience, Inc. 2021. MassARRAY® SARS-CoV-2 Panel Instructions for Use.
- 309 20. Hernandez MM, Gonzalez-Reiche AS, Alshammary H, Fabre S, Khan Z, van De Guchte A, Obla
- 310 A, Ellis E, Sullivan MJ, Tan J, Alburquerque B, Soto J, Wang C-Y, Sridhar SH, Wang Y-C, Smith
- 311 M, Sebra R, Paniz-Mondolfi AE, Gitman MR, Nowak MD, Cordon-Cardo C, Luksza M, Krammer
- 312 F, van Bakel H, Simon V, Sordillo EM. 2021. Before the surge: Molecular evidence of SARS-
- 313 CoV-2 in New York city prior to the first report. bioRxiv. medRxiv.
- 21. Mostafa HH, Hardick J, Morehead E, Miller J-A, Gaydos CA, Manabe YC. 2020. Comparison of
- 315 the analytical sensitivity of seven commonly used commercial SARS-CoV-2 automated molecular
- 316 assays. J Clin Virol 130:104578.

317	22.	Nalla AK.	Casto AM.	Huang	M-LW.	Perchetti	GA. Sam	poleo R	. Shrestha I	L. Wei	Y. Zhu H.
					,				,		- ,,

- 318 Jerome KR, Greninger AL. 2020. Comparative Performance of SARS-CoV-2 Detection Assays
- 319 Using Seven Different Primer-Probe Sets and One Assay Kit. J Clin Microbiol 58.
- 320 23. SoRelle JA, Mahimainathan L, McCormick-Baw C, Cavuoti D, Lee F, Bararia A, Thomas A,
- 321 Sarode R, Clark AE, Muthukumar A. 2020. Evaluation of symptomatic patient saliva as a sample
- 322 type for the Abbott ID NOW COVID-19 assay. bioRxiv. medRxiv.
- 323 24. Lu J, Becker D, Sandoval E, Amin A, De Hoff P, Diets A, Leonetti N, Lim YW, Elliott C, Laurent
- 324 L, Grzymski J. 2020. Saliva is less sensitive than nasopharyngeal swabs for COVID-19 detection in
- 325 the community setting. bioRxiv. medRxiv.
- 326 25. Pasomsub E, Watcharananan SP, Boonyawat K, Janchompoo P, Wongtabtim G, Suksuwan W,
- 327 Sungkanuparph S, Phuphuakrat A. 2021. Saliva sample as a non-invasive specimen for the
- 328 diagnosis of coronavirus disease 2019: a cross-sectional study. Clin Microbiol Infect 27:285.e1-

329 285.e4.

# 330 TABLES

331

- 332 Table 1. Detection of SARS-CoV-2 nucleic acids in saliva across Roche and Agena commercial
- 333 systems
- 334
- 335

Roche										
		Positive	Negative	Total						
ena	Positive	33	1*	34						
Ag	Negative	1	25	26						
	Total	34	26	60						

\*Presumptive positive by Roche

-

336

337	Table 2. LoD of SARS-CoV-2 nucleic acids in spiked saliva on the Agena MassARRAY® platform	
338		

	No. d	etected		Probit							
	12500	6250	3125	1562.5	781.3	390.6	195.3	0.0	Exp LoD <sup>a</sup>	LoD <sup>b</sup>	95% CI <sup>c</sup>
Overall	10/10	10/10	10/10	10/10	1/10	0/10	0/10	0/10	1562.5	NA	NA
N1	10/10	10/10	10/10	9/10	2/10	0/10	0/10	0/10	3125.0	1745.5	(1336, 4069)
N2	10/10	10/10	10/10	10/10	1/10	0/10	0/10	0/10	1562.5	NA	NA
N3	10/10	10/10	4/10	1/10	0/10	0/10	0/10	0/10	6250.0	5257.8	(3989, 12801)
ORF1	10/10	10/10	8/10	8/10	0/10	0/10	0/10	0/10	6250.0	3544.7	(2502, 8161)
Orf1ab	0/10	0/10	0/10	0/10	0/10	0/10	0/10	0/10	>12500	NA	NA

339

<sup>a</sup>Experimental (Exp) LoD determined by concentration at which detection is ≥95% <sup>b</sup>LoD determined by probit analysis. "NA" reflects inability to perform probit analyses due to lack of sufficient probit points 340

341 °95% fiduciary confidence interval

#### 342 FIGURES

343

# Fig. 1. Quantitative comparison of SARS-CoV-2 targets detected in clinical saliva specimens.

- 345 Scatter plots depict the number of SARS-CoV-2 targets on the Agena platform detected and the
- 346 corresponding Roche cycle threshold (Ct) for each clinical saliva specimen. (A) Ct values for Roche
- 347 target T1 (Orf1ab) and (B) Roche target T2 (E gene) are depicted for individual clinical saliva
- 348 specimens. Medians are depicted in each column. Statistically significant differences are depicted (e.g.,
- 349 \*, p<0.05; \*\*, p<0.01; \*\*\*, p<0.001, \*\*\*\*, p<0.0001) based on student's t-test or Mann-Whitney non-
- 350 parametric test depending on whether data was normally distributed (see Methods).

# Fig. 1



# 351 Fig. 2. Evaluation of Roche and Agena SARS-CoV-2 target sensitivity. (A) Bar graph depicts

- 352 percent of spiked saliva specimens detected overall by the Agena MassARRAY® platform at five
- 353 different concentration (log). Overlaid are the individual sensitivities of the five Agena targets at each
- 354 concentration. (B) Scatter plot of Ct values of Roche T1 (pink) and T2 (blue) targets across
- 355 concentrations (log) of spiked saliva specimens at six different concentrations. Mean, standard error of
- the mean, and line of best fit with 95% confidence intervals are depicted for each target. Above each
- 357 concentration is the percent of replicates detected by T1 or T2 targets.

# Fig. 2



# 358 SUPPLEMENTAL FIGURES

359

360	Fig. S1.	Quantitation	of in-house	SARS-CoV	-2 standard.	Linear reg	gression of	commercial	standard
-----	----------	--------------	-------------	----------	--------------	------------	-------------	------------	----------

- 361 in negative NP matrix run alongside three dilutions of pooled positive SARS-CoV-2 NP clinical
- 362 specimens. (A) Mean (±SEM) Roche target T1 Ct values and (B) target T2 Ct values of seven serial
- 363 dilutions of commercial standard plotted with lines of best fit. Correlation coefficients and p-values are
- 364 annotated for each standard curve. Concentrations for three dilutions (D1, D2, D3) of in-house standard
- 365 were extrapolated from T1 and T2 lines of best fit (dotted green lines) to determine the concentration of
- 366 the in-house standard.

367

# Fig. S1

